You searched for "VEGF"
Neovascular AMD: fresh recommendations underline standards of best practice
The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting
The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...Do steroids prevent progression to proliferative diabetic retinopathy (PDR)?
There is continuing debate on the merits of pan-retinal photocoagulation (PRP) for severe pre-proliferative and proliferative DR versus the newer therapies that inhibit vascular endothelial growth factor (VEGF). This has been hotly debated [1] following the publication of findings from...
2018 update on intravitreal injections
In this review article the authors have highlighted the standardised and structured approach to intravitreal injections (IVI) by examining the recent evidence-based literature. IVI is the most commonly performed procedure worldwide with low potential risk of endophthalmitis. IOP spikes are...
How does cataract surgery affect eyes with wet AMD?
In this retrospective cohort study the authors’ primary objective was to assess whether cataract surgery in eyes with wet age-related macular degeneration (AMD), triggered its progression. The surgical group comprised of 40 eyes versus 42 eyes in the non-surgical control...BARS (British Association of Retinal Screening) Conference 2023
Why not join us at the BARS Conference 2023 in the vibrant city of Bristol, at the Marriott Hotel on Thursday 28 and Friday 29 September. This year there is something for everyone with an interest in diabetic eye screening....My top five: Emerging alternatives to manage and treat nAMD
Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
Aqueous humour cytokine levels in PCV and nAMD
This study looks into the possible roles of various cytokines or growth factors in the pathogenesis of exudative age-related macular degeneration (AMD) by comparing aqueous levels of 14 cytokines between eyes with polypoidal choroidal vasculopathy (PCV) and those with neovascular...
Intravitreal dexamethasone implant for diabetic macular oedema
The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...
RPE tears in cases of IPCV
The aim of this study was to investigate the occurrence, characteristics, management and prognosis of retinal pigment epithelium (RPE) tears in patients with polypoidal choroidal vasculopathy (PCV). Medical records of previous cases were reviewed over an eight-year period from a...
